ROCKLAGE SCOTT M — SEC Form 4 filings
SEC reporting owner CIK 1219014. 11 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-02 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 5,656,074 shares, $16,526,031 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 34 legs across 9 filings — 1,438,759 shares, $6,823,991 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 5,206,074 shares @ $2.31 ($12,026,031) in Skye Bioscience, Inc., filed 2024-02-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | 10% owner | 6 | 2 legs · 5,656,074 sh · $16,526,031 | 21 legs · 907,474 sh · $2,755,947 | — |
| Entrada Therapeutics, Inc. (TRDA) | 10% owner | 5 | — | 13 legs · 531,285 sh · $4,068,043 | — |
Form 4 filings — ROCKLAGE SCOTT M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH | Sale (S): 32,607 @ $1.91 · Sale (S): 1,285 @ $1.91 | EDGAR |
| 2026-08-20 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-10 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Schwab Andrew J. | Sale (S): 10,494 @ $7 · Sale (S): 52,317 @ $6.85 | EDGAR |
| 2026-08-03 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Schwab Andrew J. | Sale (S): 114,756 @ $6.93 · Sale (S): 1,718 @ $6.85 | EDGAR |
| 2025-11-18 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Schwab Andrew J. | Sale (S): 200,000 @ $8.80 | EDGAR |
| 2025-08-22 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-07-11 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Schwab Andrew J. | Sale (S): 20,065 @ $7.50 · Sale (S): 6,935 @ $7.50 | EDGAR |
| 2025-07-01 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with 5AM Ventures V, L.P., 5AM Partners V, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, Schwab Andrew J. | Sale (S): 55,735 @ $6.91 · Sale (S): 19,265 @ $6.91 · Sale (S): 18,578 @ $6.81 · Sale (S): 6,422 @ $6.81 · Sale (S): 18,578 @ $7.12 · Sale (S): 6,422 @ $7.12 | EDGAR |
| 2024-09-13 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH | Sale (S): 214,556 @ $6.60 · Sale (S): 36,504 @ $6.60 · Sale (S): 1,440 @ $6.60 · Sale (S): 11,758 @ $6.06 · Sale (S): 2,000 @ $6.06 · Sale (S): 79 @ $6.06 | EDGAR |
| 2024-03-15 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH | Purchase (P): 450,000 @ $10 | EDGAR |
| 2024-02-02 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH | Purchase (P): 5,206,074 @ $2.31 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1219014 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →